ERBB2 and breast carcinoma: Within molecular subtypes of breast cancer, splitting women by radiomic phenotype assignment showed no significant difference in RFS for the HR + /HER2- subgroup (p = 0.3) and significant differences within the HER2 + and Triple Negative subtypes (both p = 0.02) (Fig. 2).